Passage Bio

Passage Bio EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Passage Bio (PASG) as of Nov 17, 2026 is -0.12. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 0.34 — a change of -135.64% (lower).

EV/EBITDA

-0.12

YoY

-135.64%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Passage Bio is 2025 -0.12 . EV/EBITDA (Enterprise Value to EBITDA) of Passage Bio was 2024 0.34 . It decreases by -135.64% lower compared to the previous year.

The Passage Bio EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-0.20 USD
Jan 1, 2019
3.53 USD
Jan 1, 2020
2.46 USD
Jan 1, 2021
1.55 USD
Jan 1, 2022
0.98 USD
Jan 1, 2023
0.60 USD
Jan 1, 2024
0.34 USD
Jan 1, 2025
-0.12 USD
The Passage Bio EV/EBITDA history
YEAREV/EBITDAYoY
-0.12-135.64%
0.34-44.08%
0.60-38.06%
0.98-37.15%
1.55-36.81%
2.46-30.47%
3.53-1,909.71%
-0.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Passage Bio Stock analysis

What does Passage Bio do? Passage Bio, Inc. develops genetic medicines for rare monogenic central nervous system diseases. The company focuses on six AAV-delivered therapeutics, including PBGM01 for gangliosidosis (GM1), PBFT02 for frontotemporal dementia (FTD), and PBKR03 for Krabbe disease. PBGM01 uses an AAVhu68 capsid to deliver a functional GLB1 gene encoding beta-galactosidase, PBFT02 uses AAV1 to deliver a GRN gene encoding progranulin, and PBKR03 employs AAVhu68 to deliver a GALC gene. The firm's products target specific genetic deficiencies in the central nervous system and peripheral tissues. Passage Bio's revenue model is based on developing and advancing its therapeutic pipeline. The company generates income through partnerships and potential future sales of its AAV-based therapies once approved. The primary buyers of its products are pharmaceutical companies seeking to license or co-develop these therapies. The target segments include patients with rare genetic disorders such as GM1, FTD, and Krabbe disease, who require specialized treatments due to the monogenic nature of their conditions. The firm's pipeline consists of six therapeutics, with PBGM01, PBFT02, and PBKR03 being the most advanced. These therapies are designed to address unmet medical needs in rare CNS diseases. Passage Bio's strategy involves leveraging its AAV delivery technology to create targeted treatments that can be commercialized through partnerships with larger pharmaceutical firms. Passage Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Passage Bio stock

EV/EBITDA (Enterprise Value to EBITDA) of Passage Bio is -0.12 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Passage Bio changed from 0.34 to -0.12, representing a -135.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Passage Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Passage Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Passage Bio

All Key Metrics — Passage Bio